1.60 USD
-0.12
6.98%
At close Updated Jun 5, 4:00 PM EDT
Pre-market
After hours
1.61
+0.01
0.63%
1 day
-6.98%
5 days
11.11%
1 month
-3.03%
3 months
19.4%
6 months
1.27%
Year to date
20.3%
1 year
-85.32%
5 years
-99.9%
10 years
-99.84%
 

About: BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Employees: 13

0
Funds holding %
of 8,076 funds
0
Positive news %
of 10 articles
Price charts implemented using Lightweight Charts™